FDA approves labeling changes for ED drugs

Share this article:
The FDA has approved some labeling changes to erectile dysfunction drugs— including Viagra, Cialis, and Levitra—to display more prominently an existing risk on the potential for sudden hearing loss. The changes were also made to Pfizer's Revatio, which contains the same active ingredient (sildenafil) as Viagra.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.